MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopaminergics"

  • 2025 International Congress

    Dopamine-Responsive Post-Anoxic Parkinsonism

    T. Liu, J. Ahlskog, J. Bower, O. Kantarci, R. Savica (Rochester, USA)

    Objective: To describe a retrospective case series of five cases of dopamine-responsive post-anoxic parkinsonism. Background: Parkinsonism following hypoxic ischemic damage of the basal ganglia is…
  • 2025 International Congress

    Levodopa Effects In Swedd: Clinical And Kinematic Insights From A Case Report

    D. Birreci, L. Angelini, A. Martini, S. Grandolfo, M. de Riggi, S. Aloisio, M. Bologna (Rome, Italy)

    Objective: To investigate the clinical and neurophysiological effects of levodopa treatment in a patient diagnosed with SWEDD. Background: A subset of patients with clinical features…
  • 2025 International Congress

    Antiparkinson Medication Reduces the Probability of the Multiple Step Saccade Pattern During a Memory-Guided Saccade Task

    M. Munoz, J. Reilly, E. Zou, Y. Rivera, G. Pal, L. Verhagen Metman, L. Goelz, D. Corcos, F. David (Chicago, USA)

    Objective: We wanted to determine how the multiple step saccade pattern responds to antiparkinson medication, as it has been proposed to use this pattern as…
  • 2025 International Congress

    Inpatient Multimodal Intensive Care in Moderately Advanced Parkinson’s Disease: Role Of Medication Adjustment In Outcome Measures

    N. Elayan, L. Rubin, M. Mccrossin, C. Roberts, H. Shakil, A. Di Rocco, M. Ghilardi (Long Island, USA)

    Objective: In this study, we wish to determine whether medication changes play a major role in the improvements observed after in-patient multimodal intensive neurorehabilitation and…
  • 2025 International Congress

    Classification of Medication State in Parkinson’s Disease Patients with and without Fluctuations using Facial Videos

    I. Boura, V. Skaramagkas, G. Karamanis, I. Kyprakis, D. Fotiadis, Z. Kefalopoulou, M. Tsiknakis, C. Spanaki (Heraklion, Crete, Greece)

    Objective: This study presents a unique, interpretable Dual-Stream Transformer model for classifying medication state in patients with Parkinson’s disease (PD) using facial videos. Background: Recent…
  • 2024 International Congress

    Identifying the Most Sensitive Patient-reported Items from the MDS-UPDRS that Predict Initiation of PD Medications in Early Disease

    H. Zou, C. Goetz, G. Stebbins, T. Mestre, S. Luo (Durham, USA)

    Objective: Objective: To determine the most sensitive combination of MDS-UPDRS Parts IB and II items that accurately predicted the clinically relevant target of dopaminergic therapy…
  • 2024 International Congress

    Maintaining Isometric Contraction in Parkinson’s Disease: Effect of PD-Medication on EMG Amplitude

    B. Afsharipour, F. Roy, M. Schindle, F. Ba, M. Gorassini, T. Sankar (Edmonton, Canada)

    Objective: To quantify muscle activity changes in PD with dopaminergic medication. Background: Parkinson's disease (PD) is characterized by motor symptoms that improve with dopaminergic medication.…
  • 2023 International Congress

    Levodopa-induced orthostatic hypotension in parkinsonism: a red flag of autonomic failure

    I. Cani, P. Guaraldi, G. Giannini, L. Sambati, G. Barletta, P. Cortelli, G. Calandra-Buonaura (Bologna, Italy)

    Objective: To evaluate the cardiovascular and hemodynamic effect of LD in patients with parkinsonism on chronic LD treatment. Background: Levodopa (LD) is the main treatment…
  • 2023 International Congress

    Observations on 5 Parkinson’s patients taking Mucuna pruriens as natural source of levodopa

    S. Elsas (Arlesheim, Switzerland)

    Objective: To explore potential benefits and tolerability of extracts from Mucuna pruriens for dopaminergic treatment of Parkinson’s patients. Background: Capsules containing freeze-dried, aqueous extract from…
  • 2023 International Congress

    The effect of dopaminergic medication on force fluctuation in Parkinson’s disease

    B. Afsharipour, M. Schindle, F. Roy, F. Ba, M. Gorassini, T. Sankar (Edmonton, Canada)

    Objective: To quantify and compare muscle force variability during isometric dorsiflexion in male patients with Parkinson's Disease (PD), in the ON- versus OFF-medication state. Background:…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley